Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF)

Not Applicable

Terminated

• Conditions: Idiopathic Pulmonary Fibrosis
• Interventions: Other: Usual Care of IPF; Other: Telenursing; Other: Telenursing and Remote Monitoring

• Registration Number: NCT03562247
• Lead Sponsor: Vanderbilt University Medical Center

Brief Summary

Numerous studies show that remote monitoring and/or telenursing improves outcomes for patients especially those with chronic diseases. It is proposed that structured telenursing with non-invasive home monitoring of forced vital capacity and oxygen saturation in newly diagnosed patients with IPF will decrease hospitalizations for respiratory illness, increase compliance with therapies, and ultimately increase quality of life.

Detailed Description

Patients undergoing evaluation for and who are diagnosed with Idiopathic Pulmonary Fibrosis at Vanderbilt Medical Center from August 1, 2018, will be asked to participate. If agrees, and after signing the consent form, patients will be randomized into one of three arms: Usual Care, Usual Care with Telenursing, or Usual Care with Telenursing and Remote Monitoring. Patients will be asked to remain in the study for a minimum of three years.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-06-14
• Study First Submitted QC: 2018-06-14
• Study First Posted: 2018-06-19
• Study Start: 2018-08-01
• Primary Completion: 2020-05-26
• Study Completion: 2020-05-26
• Results First Submitted: 2022-02-14
• Status Verified: 2023-03
• Results First Submitted QC: 2023-03-31
• Last Update Submitted: 2023-03-31
• Results First Posted: 2024-01-16
• Last Update Posted: 2024-01-16

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

1. Patient must be newly diagnosed with IPF by a Vanderbilt pulmonologist according to the 2011 American Thoracic Society Guidelines. If the patient has been diagnosed by local pulmonologist and started on FDA-approved treatment, then must have been started on treatment within 6 months of Vanderbilt University Medical Center-based diagnosis.
2. Willingness to complete Quality of Life and Compliance Questionnaires at 6-month intervals either via an on-line process (RED Cap survey) or paper-based.
3. Willingness to participate in phone calls/video calls with the nurse practitioner or nurse case manager, if assigned to Arm 2 or Arm 3.
4. Willingness to complete and monitor daily health assessments, if assigned to Arm 3.
5. Willingness to share objective data via a provided electronic web-based portal, electronically via email, fax, or regular mail.
6. Willingness to notify, or allow notification, of study involvement with local pulmonary practices.

Read More

Exclusion Criteria

1. Diagnosed with any other interstitial lung disease.
2. Diagnosed and began treatment > 6 months before the VUMC-based diagnosis date.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Usual Care of IPF	Usual Care of IPF	Newly diagnosed patients will continue to receive excellent healthcare as currently given in management of the lung disease
Telenursing	Telenursing	Patients will receive usual care with structured phone calls from the nurse practitioner and/or case manager occuring more frequently earlier in the diagnosis to help the patient and care giver understand all aspects of the disease and it time will evolve to managing symptoms outside of out-patient clinic visits.
Telenursing and Remote Monitoring	Usual Care of IPF	Patients will receive usual care with telenursing and will be given a hand held spirometer and puse oximeter and be asked to take daily measurements and report these via an electronic HIPAA approved secured platform for evaluation by the telenursing team.
Telenursing and Remote Monitoring	Telenursing	Patients will receive usual care with telenursing and will be given a hand held spirometer and puse oximeter and be asked to take daily measurements and report these via an electronic HIPAA approved secured platform for evaluation by the telenursing team.
Telenursing	Usual Care of IPF	Patients will receive usual care with structured phone calls from the nurse practitioner and/or case manager occuring more frequently earlier in the diagnosis to help the patient and care giver understand all aspects of the disease and it time will evolve to managing symptoms outside of out-patient clinic visits.
Telenursing and Remote Monitoring	Telenursing and Remote Monitoring	Patients will receive usual care with telenursing and will be given a hand held spirometer and puse oximeter and be asked to take daily measurements and report these via an electronic HIPAA approved secured platform for evaluation by the telenursing team.

Primary Outcome Measures

Name	Time	Method
The Number Hospitalization Events Resulting From a Respiratory Illness	Baseline to 21 months	The number hospitalization events resulting from a respiratory illness

Secondary Outcome Measures

Name	Time	Method
The Number of Respiratory Events That Indicate a Worsening of Idiopathic Pulmonary Fibrosis (IPF)	Baseline to 21 months	The number of respiratory events that indicate a worsening of Idiopathic Pulmonary Fibrosis (IPF)
The Number of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF)	Baseline to 21 months	The Number of Acute Exacerbations of IPF
The Percentage of Change in Forced Vital Capacity (FVC) Measured by Spirometry	Baseline to 21 months	The percentage of change in home-measured forced vital capacity (FVC) compared to clinic-measured FVC via spirometry
The Severity of Depression as Measured by the Adapted Mental Health America Depression Screening Tool	Up to 21 months	The adapted Mental Health America Depression Screening Tool is an 8 question self-administered questionnaire that scores patient-reported symptoms of depression. The possible score for each question ranges from 0-3. The total questionnaire score range is 0-24. Total scores of 0-6 indicate 'none to mild depression' and scores of 16-24 indicate 'severe depression'. Data from participant visits at baseline, 3 months, 9 months, 15 months and 21 months were combined and averaged to calculate a single value.
The Severity of Anxiety as Measured by the Adapted New Zealand Health Promotion Agency Anxiety Self-Test	Baseline to 21 months	The adapted New Zealand Health Promotion Agency Anxiety Self-Test is an 8 question self-administered questionnaire that scores patient-reported symptoms of anxiety. The possible score for each question ranges from 0-3. The total questionnaire score range is 0-24. Total scores of 0-8 indicate 'none to mild anxiety' and scores of 16-24 indicate 'severe anxiety'. Data from participant visits at baseline, 3 months, 9 months, 15 months and 21 months were combined and averaged to calculate a single value.
The Number of Days From Idiopathic Pulmonary Fibrosis (IPF) Diagnosis to First Hospitalization for Respiratory Illness	Baseline to 21 months	The total combined number of days for all participants in each arm from the date of IPF diagnosis to the date of first hospitalization for respiratory illness.
The Severity of Dyspnea as Measured by the Modified Medical Research Council (mMRC) Dyspnea Scale	Baseline to 21 months	Dyspnea (shortness of breath) was assessed using the mMRC, a single item (0-4) scale assessing current level of dyspnea. The mMRC comprised of five statements that describe almost the entire range of respiratory disability from none (Grade 0) to almost complete incapacity (Grade 4). The mMRC categorized participants into low dyspnea (Grades 0-1) and high dyspnea (Grades 2-4).

Trial Locations

Locations (1)

Vanderbilt University Medical Center; 🇺🇸 Nashville, Tennessee, United States